← All ingredients

GHRH analog + selective GHRP (ghrelin-receptor agonist)

CJC-1295 / Ipamorelin

GHRH analog plus selective ghrelin-receptor agonist, synergistic GH-pulse stack for recovery and body composition.

• Half-lifeCJC-1295: ~8 days (DAC version) · Ipamorelin: ~2 hours
• Dose range100–300 mcg/day total stack · daily before bed
• Reconstituted stability28 days, 2–8 °C
• VerificationCOA included

Mechanism

How it works.

CJC-1295 amplifies endogenous GH pulses by binding GHRH receptors; Ipamorelin binds the ghrelin receptor (GHSR-1a) to trigger a clean pulse without cortisol or prolactin elevation. Combined effect is larger and more selective than either alone.

Research

What the research shows.

Research shows elevated IGF-1 (a downstream marker of GH activity), improved sleep architecture (deeper SWS), and enhanced soft-tissue repair. Effects compound over a 12-week cycle.

A pairing of two complementary peptides: CJC-1295 (a long-acting GHRH analog that increases the amplitude of GH pulses) and Ipamorelin (a selective GHRP that triggers a clean GH release without affecting cortisol or prolactin).

Contraindications

When not to use.

Active malignancy. Diabetic ketoacidosis or severe insulin resistance. Pregnancy. Pediatric use without clinical oversight.

Optimal pairings

Stacks well with.

Pentadecapeptide · Synthetic gastric peptide BPC-157 View → Coenzyme · Cellular energy + sirtuin pathway substrate NAD⁺ View → Stabilised GHRH analog (codename for restricted compound) Tesa View →

Tool Calculate dose → Reconstitution math + syringe units Tool Build a stack → Get a curated protocol with this compound Shop Buy CJC-1295 / Ipamorelin → COA included · cold-chain dispatched

Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.